Tactile Medical Q3 2026: Airway Clearance Drop Masks Lymphedema Surge
As seen on the 24/7 Wall St. homepage on November 2, 2026.
A 25% drop in airway clearance revenue, tied to a distributor inventory transition around the new AffloVest, pushed Tactile Medical below expectations on both lines. Management reaffirmed full-year revenue guidance and raised its adjusted EBITDA outlook, framing the shortfall as timing.
Continue ReadingShow less
Tactile Systems Technology reported Q3 2026 revenue of $91.86 million, up 7% year-over-year, missing expectations on both revenue and EPS. The miss obscures a sharp divide between the company's two main businesses.
Lymphedema revenue climbed 13% to $81.84 million, marking five consecutive quarters of double-digit year-over-year growth. Airway clearance revenue fell 25% to $10.02 million, a drop the company attributed entirely to a distributor inventory transition tied to the launch of the next-generation AffloVest system in Q2 2026.
Operating expenses rose 13% to $60.9 million on growth initiatives, pulling operating income below the prior-year level. Gross margin expanded to 77%, its 12th consecutive quarter of expansion, while Adjusted EBITDA held flat.
Sponsored
Management reaffirmed full-year 2026 revenue guidance of $360 million to $366 million and raised its Adjusted EBITDA outlook. The company also repurchased stock in the quarter under a buyback program running through November 2027.
On the regulatory front, Tactile received FDA 510(k) clearance expanding the LymphaTech 3D Scanner's indication and submitted a 510(k) application for the Flexitouch Pro. Whether the airway clearance segment rebounds as distributor inventories normalize will be the key question for the fourth quarter.
Mentioned: TCMD